Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Binimetinib in RAS-Mutant Cancers (ComboMATCH EAY191-A3)
NCT05554367Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2023
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of palbociclib in ovarian serous adenocarcinoma, pancreatic cancer (PC), solid tumor, sponsored by National Cancer Institute. Started Dec 2023; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
ovarian serous adenocarcinomapancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT05554367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554367.